Johnson & Johnson will be launching a series of human tests for experimenting on the Human Immunodeficiency Virus (HIV) vaccine in Europe and the US within a year.
This new vaccine is basically a tetravalent mosaic. The aim of the vaccine is to increase the immunity of the body against different types of HIV.
There will be almost four thousand male participants for the clinical trials that have been planned for this year. In the TRAVERSE study, this is phase 2. The participants will be given six shots in four sessions and the results of the trials will be published in the year 2023.
The objective of this study is to develop immunity against HIV for preventing Acquired Immune Deficiency Syndrome (AIDS). The HIV fights against the cells of the immune system and lower the body’s defense against diseases. AIDS is when the immune system of a patient is destroyed and has no longer the ability to protect the body. At this stage, any type of infection, major or minor, gets life-threatening for a patient.
According to the UNAIDS, that is the joint program of United Nations on HIV/AIDS, there were almost 36.9 million people having HIV in the year 2017 and roughly 1.8 million of those who are infected are children having the ages of 15 years old and below. But on a positive note, there has been a 51 percent decrease in AIDS-related deaths in the year 2017 compared to the year 2004, when the danger of the virus peaked.
The advancement of the tetravalent mosaic HIV vaccine was also called the TRAVERSE study. In the year 2018, J&J demonstrated the results of their study in Madrid, Spain at the HIV Research for Prevention Conference. According to Johnson and Johnson, the results depicted promising and significant outcomes.